Cryo Cell International Inc: Form 10-Q for the period ended Aug 31, 2023
Filed with the SEC on Oct 12, 2023 and accepted by EDGAR at Oct 12, 2023, 21:01 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-08-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-06-01 to 2023-08-31 | $7.9m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 9 months2022-12-01 to 2023-08-31 | $23.5m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months2023-06-01 to 2023-08-31 | $2.2m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2022-12-01 to 2023-08-31 | $6.4m | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2023-06-01 to 2023-08-31 | $344.1k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2022-12-01 to 2023-08-31 | $727.6k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2023-06-01 to 2023-08-31 | $3.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2022-12-01 to 2023-08-31 | $11.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-06-01 to 2023-08-31 | $1.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2022-12-01 to 2023-08-31 | $3.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-06-01 to 2023-08-31 | $469.6k | us-gaap:InterestExpense |
| Interest expense | 9 months2022-12-01 to 2023-08-31 | $1.4m | us-gaap:InterestExpense |
| Income tax | 3 months2023-06-01 to 2023-08-31 | $387.1k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2022-12-01 to 2023-08-31 | $960.2k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-06-01 to 2023-08-31 | $680.6k | us-gaap:NetIncomeLoss |
| Net income | 9 months2022-12-01 to 2023-08-31 | $1.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-06-01 to 2023-08-31 | $0.08 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2022-12-01 to 2023-08-31 | $0.20 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-06-01 to 2023-08-31 | $0.08 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2022-12-01 to 2023-08-31 | $0.20 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-06-01 to 2023-08-31 | 8,342,067 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2022-12-01 to 2023-08-31 | 8,374,939 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2022-12-01 to 2023-08-31 | $5.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2022-12-01 to 2023-08-31 | $5.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months2022-12-01 to 2023-08-31 | $799.0k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2023-08-31 | $584.0k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-08-31 | $9.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-08-31 | $69.8m | us-gaap:Assets |
| Current liabilities | At period end2023-08-31 | $18.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-08-31 | $69.8m | us-gaap:Liabilities |
| Long-term debt | At period end2023-08-31 | $8.6m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2023-08-31 | −$16.2k | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-23-053143. Last ingested by Listed: Oct 24, 2026, 14:58 ET. Listed shows no prices and gives no investment advice.